Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.29% | -0.18% | +4.36% |
Sales 2024 * | 954M 76.41B | Sales 2025 * | 1.1B 88.07B | Capitalization | 4.9B 392B |
---|---|---|---|---|---|
Net income 2024 * | 370M 29.62B | Net income 2025 * | 484M 38.75B | EV / Sales 2024 * | 6.18 x |
Net Debt 2024 * | 1B 80.13B | Net Debt 2025 * | 422M 33.78B | EV / Sales 2025 * | 4.84 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
9.46
x | Employees | 373 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.92% |
Latest transcript on Halozyme Therapeutics, Inc.
1 day | +0.29% | ||
1 week | -0.18% | ||
Current month | -5.19% | ||
1 month | -5.30% | ||
3 months | +12.74% | ||
6 months | +15.55% | ||
Current year | +4.36% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 05/01/14 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 31/12/14 |
Mark Snyder
CMP | Compliance Officer | 57 | 02/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 30/07/06 |
Chairman | 59 | 04/08/15 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 02/02/23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 5 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 38.57 | +0.29% | 547,134 |
25/04/24 | 38.46 | -1.69% | 693,350 |
24/04/24 | 39.12 | +0.38% | 620,516 |
23/04/24 | 38.97 | +0.67% | 557,948 |
22/04/24 | 38.71 | +0.18% | 525,232 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.36% | 4.9B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HALO Stock